What medications or supplements are affected in a patient with a CYP2D6 (cytochrome P450 2D6) variation?

CYP2D6 Variation: Affected Medications and Clinical Management

Patients with CYP2D6 genetic variations require careful medication selection and dose adjustment for numerous cardiovascular, psychiatric, oncologic, and analgesic drugs, as CYP2D6 metabolizes approximately 25% of current medications and exhibits marked genetic polymorphism affecting drug efficacy and toxicity. 1, 2

Major Drug Classes Affected by CYP2D6 Variation

Antiarrhythmic Medications

Flecainide and propafenone are both metabolized by CYP2D6, and poor metabolizers (7-10% of the population) can experience significantly increased plasma concentrations leading to toxicity. 1

• Flecainide metabolism is affected by CYP2D6 inhibitors including quinidine, fluoxetine, and tricyclics, with dual impairment (genetic plus drug interaction) causing marked plasma concentration increases 1
• Propafenone exhibits increased beta-blockade in poor metabolizers due to accumulation of the parent drug, which is a more potent beta-blocker than its metabolites 1, 2
• Quinidine itself inhibits CYP2D6, increasing concentrations of tricyclic antidepressants, metoprolol, and antipsychotics while decreasing codeine efficacy 1

Beta-Blockers

Metoprolol demonstrates the strongest gene-dose effect among beta-blockers, with poor metabolizers experiencing excessive drug concentrations and increased risk of hypotension and bradycardia. 2, 3

• Metoprolol concentrations can increase 2- to 5-fold in poor metabolizers, with corresponding increases in beta-blocking effects 4, 3
• Carvedilol, propranolol, and timolol show lesser CYP2D6 gene-dose effects compared to metoprolol 2, 3
• Ultrarapid metabolizers may experience treatment failure with standard metoprolol doses due to subtherapeutic drug levels 3

Antidepressants

Selective serotonin reuptake inhibitors (SSRIs) including fluoxetine and paroxetine are both CYP2D6 substrates and potent CYP2D6 inhibitors, creating complex drug-drug interaction risks. 4, 5, 6

• Paroxetine inhibits CYP2D6, increasing concentrations of tricyclic antidepressants, metoprolol, antipsychotics, and reducing codeine efficacy 5
• Fluoxetine inhibits CYP2D6 activity and may make normal metabolizers resemble poor metabolizers, requiring dose reductions of concomitant CYP2D6 substrates 6
• Tricyclic antidepressants (nortriptyline, amitriptyline, imipramine, desipramine) show gene-dose effects, with poor metabolizers experiencing toxic concentrations at conventional doses 4, 5, 7
• A case report documented a CYP2D6*5/*10B poor metabolizer who developed toxic nortriptyline levels with dry mouth, constipation, and dizziness on standard dosing 7

Antipsychotic Medications

Perphenazine, zuclopenthixol, risperidone, and haloperidol demonstrate significant relationships between CYP2D6 genotype and steady-state concentrations. 8, 9

• Paroxetine 20 mg daily increased risperidone plasma concentrations approximately 4-fold in one study 5
• Therapeutic drug monitoring is strongly recommended for haloperidol, chlorpromazine, fluphenazine, perphenazine, risperidone, and thioridazine 8
• Thioridazine is contraindicated with paroxetine and fluoxetine due to risk of serious ventricular arrhythmias and sudden death from elevated thioridazine levels 5, 6
• Dronedarone inhibits CYP2D6 and increases concentrations of beta-blockers and other substrates 1

Opioid Analgesics

Codeine requires CYP2D6 conversion to morphine for analgesic effect; poor metabolizers experience treatment failure while ultrarapid metabolizers risk toxicity. 10, 8, 2

• CYP2D6 inhibitors block codeine-to-morphine conversion, resulting in inadequate analgesia 10, 5
• Tramadol efficacy is decreased in poor metabolizers due to reduced formation of active O-desmethyl-tramadol 8, 2
• Methadone clearance is reduced in poor metabolizers, potentially increasing toxicity risk 8
• Heightened perioperative vigilance is required to avoid coadministration of CYP2D6 inhibitors with opioid prodrugs 10

Tamoxifen (Breast Cancer Treatment)

Tamoxifen is a prodrug requiring CYP2D6 metabolic activation to endoxifen; CYP2D6 poor metabolizers and patients on CYP2D6 inhibitors may experience therapeutic failure. 11, 12, 5, 8

• Strong and moderate CYP2D6 inhibitors (paroxetine, fluoxetine, bupropion, duloxetine) should be avoided in tamoxifen-treated patients; if unavoidable, switch to an aromatase inhibitor 12, 5
• Patients carrying CYP2D6*4, *5, *10, or *41 alleles had significantly more breast cancer recurrences and shorter relapse-free periods 8
• However, ESMO guidelines explicitly state that CYP2D6 polymorphism testing should not be done as a decision aid for adjuvant tamoxifen therapy (Level I, Grade E evidence) 13, 12
• Safe antidepressant alternatives include venlafaxine, citalopram, escitalopram, sertraline, desvenlafaxine, and mirtazapine with minimal CYP2D6 inhibition 12

Antiemetics

Dolasetron, ondansetron, and tropisetron are less effective in ultrarapid metabolizers, with tropisetron showing the strongest gene-concentration relationship. 8

• Granisetron is metabolized independently of CYP2D6 and may be preferred to avoid genotype-related variability 8
• CYP2D6 genotype screening prior to antiemetic treatment may allow dosing modifications 8

Critical Drug-Drug Interactions

When CYP2D6 inhibitors are prescribed, avoid concurrent use with drugs having narrow therapeutic indices metabolized by CYP2D6, particularly tamoxifen, tricyclic antidepressants, antiarrhythmics, and codeine. 10, 5, 6

Potent CYP2D6 Inhibitors to Avoid or Use Cautiously:

• Paroxetine and fluoxetine (SSRIs) 10, 5, 6
• Quinidine (antiarrhythmic) 1
• Bupropion and duloxetine (antidepressants) 12

Serotonin Syndrome Risk

Avoid combining CYP2D6 inhibitors with other serotonergic agents including triptans, tramadol, fentanyl, methadone, tapentadol, MAO inhibitors, SNRIs, and St. John's Wort. 10, 5, 6

• Serotonin syndrome is a potentially fatal toxicity state characterized by neuroexcitatory symptoms, autonomic dysfunction, and neuromuscular abnormalities 10
• Patients should be advised to alert prescribers if anxiety, agitation, panic attacks, insomnia, irritability, hostility, or unusual behavior changes occur 6

Practical Clinical Management Algorithm

Before Prescribing CYP2D6 Substrates or Inhibitors:

1. Review all current medications for CYP2D6 substrates, particularly those with narrow therapeutic indices 10, 12
2. If prescribing paroxetine or fluoxetine, specifically check for tamoxifen, tricyclic antidepressants, antiarrhythmics (flecainide, propafenone), metoprolol, codeine, and antipsychotics 10, 5, 6
3. Consider alternative antidepressants with minimal CYP2D6 inhibition (venlafaxine, citalopram, escitalopram, sertraline) for patients on tamoxifen or other critical CYP2D6 substrates 12

If Combination Therapy Is Unavoidable:

1. Reduce doses of CYP2D6 substrate drugs by 50-75% when adding a CYP2D6 inhibitor 10
2. Consider therapeutic drug monitoring for drugs with narrow therapeutic indices (tricyclic antidepressants, antipsychotics, antiarrhythmics) 10, 8
3. For tamoxifen patients requiring antidepressants, switch to an aromatase inhibitor rather than continuing tamoxifen with a CYP2D6 inhibitor 12, 5

Perioperative Considerations:

1. Avoid coadministration of CYP2D6 inhibitors with opioid prodrugs (codeine, tramadol) postoperatively 10
2. Monitor for inadequate analgesia if combination cannot be avoided and consider alternative non-prodrug opioids 10

Common Clinical Pitfalls to Avoid

Do not order CYP2D6 genotyping to guide initial tamoxifen therapy decisions—this contradicts Level I, Grade E evidence from ESMO guidelines. 13, 12

• The clinical utility of CYP2D6 genotyping for most drug therapy decisions remains unproven in prospective trials 11, 13, 12
• Drug-drug interactions (phenoconversion) from CYP2D6 inhibitor medications have clearer clinical impact than genotype alone 12, 5, 6
• Do not assume intermediate metabolizer genotype automatically requires therapy changes—focus on avoiding CYP2D6 inhibitor drugs instead 12

Do not prescribe propoxyphene for pain management in tamoxifen-treated patients, as it inhibits CYP2D6. 12

Do not ignore the 5-week washout period required after fluoxetine discontinuation before starting thioridazine due to fluoxetine's long half-life. 6

Do not combine atomoxetine with paroxetine without dose reduction—paroxetine increases atomoxetine AUC 6- to 8-fold and Cmax 3- to 4-fold. 5